Procalcitonin metabolites and macrocalcitonin in the diagnosis of hypercalcitoninemia of various origins

1. Fila M, Sobczuk A, Pawlowska E, Blasiak J. Epigenetic connection of the calcitonin gene-related peptide and its potential in migraine. Int J Mol Sci. 2022;23(11):6151.

PMID: 35682830. PMCID: PMC9181031. https://doi.org/10.3390/IJMS23116151

2. Cleland DA, Eranki AP. Procalcitonin. (Updated 2023 Apr 23). In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539794/

3. Frohlich E, Wahl R. Calcitonin and procalcitonin: Revisiting the overlooked role of C cells. Metabolism. 2026;175:156434.

PMID: 41218723. https://doi.org/10.1016/j.metabol.2025.156434

4. Trimboli P, Valderrabano P, Pitoia F, Piccardo A, Bojunga J. Appropriate and mindful measurement of serum calcitonin in patients with thyroid nodules. A white paper. Endocrine. 2024;83(1):60–64.

PMID: 37589814. PMCID: PMC10806050. https://doi.org/10.1007/S12020-023-03485-6

5. Bae YJ, Schaab M, Kratzsch J. Calcitonin as biomarker for the medullary thyroid carcinoma. Recent Results Cancer Res. 2025;223:155–82.

PMID: 40102257. https://doi.org/10.1007/978-3-031-80396-3_6

6. Kiriakopoulos A, Giannakis P, Menenakos E. Calcitonin: Current concepts and differential diagnosis. Ther Adv Endocrinol Metab. 2022;13:20420188221099344.

PMID: 35614985. PMCID: PMC9125613. https://doi.org/10.1177/20420188221099344

7. Unal MC, Bayraktar AC, Uslu T, Yener S. Multiple immunoassay interference in a patient with falsely elevated calcitonin. Arch Endocrinol Metab. 2024;68:e230074.

PMID: 37988668. PMCID: PMC10916793. https://doi.org/10.20945/2359-4292-2023-0074

8. Giannetta E, Guarnotta V, Altieri B, Sciammarella C, Guadagno E, Malandrino P et al. Endocrine tumours: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: The two-faced Janus. Eur J Endocrinol. 2020;183(6):R197–R215.

PMID: 33112280. https://doi.org/10.1530/EJE-20-0506

9. Stonyte A, Tumenaite E, Daugintyte-Petrusiene L. Elevated calcitonin in the absence of medullary thyroid carcinoma: A diagnostic challenge. Endocrine Abstracts. 2025;110 EP1593.

https://doi.org/10.1530/ENDOABS.110.EP1593

10. Takami H, Shikata J, Horie H, Sekine K, Ito K. PDN-21: Possible tumor marker for medullary thyroid carcinoma. J Surg Oncol. 1990;44(4):205–7.

PMID: 2385096. https://doi.org/10.1002/JSO.2930440403

11. Trimboli P, Lauretta R, Barnabei A, Valabrega S, Romanelli F, Giovanella L, Appetecchia M. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers. 2018;33(2):156–60.

PMID: 29707993. https://doi.org/10.1177/1724600817747518

12. Karagiannis AK, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: A new biomarker for medullary thyroid cancer? A systematic review. Anticancer Res. 2016;36(8):3803–10. PMID: 27466480.

13. Ilic J, Tausanovic K, Zoric G, Jovanovic M, Buzejic M, Ivanis S et al. Comparing the diagnostic efficacy of different calcitonin stimulation tests for sporadic medullary thyroid carcinoma: Calcium gluconate vs. calcium chloride. Diagnostics (Basel). 2025;15(15):1850.

PMID: 40804815. PMCID: PMC12345767. https://doi.org/10.3390/diagnostics15151850

14. Faggiano A, Giannetta E, Modica R, Albertelli M, Barba L, Dolce P et al. Calcium-stimulated calcitonin test for the diagnosis of medullary thyroid cancer: Results of a multicenter study and comparison between different assays. Minerva Endocrinol (Torino). 2023;48(3):253–60.

PMID: 37326573. https://doi.org/10.23736/S2724-6507.23.04017-4

15. Piticchio T, Frasca F, Trimboli P. Prevalence and significance of indeterminate calcitonin values in patients with thyroid nodules: A systematic review and meta-analysis. Rev Endocr Metab Disord. 2023;24(4):685–94.

PMID: 37254023. PMCID: PMC10404572. https://doi.org/10.1007/s11154-023-09811-7

16. Llewellyn DC, Srirajaskanthan R, Vincent RP, Guy C, Drakou EE, Aylwin SJB et al. Calcitonin-secreting neuroendocrine neoplasms of the lung: A systematic review and narrative synthesis. Endocr Connect. 2021;10(4):447–61.

PMID: 33764887. PMCID: PMC8111313. https://doi.org/10.1530/EC-21-0071

17. Doring C, Peer K, Bankov K, Bollmann C, Ramaswamy A, Di Fazio P et al. Whole-exome sequencing of calcitonin-producing pancreatic neuroendocrine neoplasms indicates a unique molecular signature. Front Oncol. 2023;13:1160921.

PMID: 37771441. PMCID: PMC10522832. https://doi.org/10.3389/fonc.2023.1160921

18. Kotla P, Udoh AI, Clement C, He J. Calcitonin-secreting neuroendocrine tumor of the lung: A diagnostic dilemma. Cureus. 2025;17(5):e83422.

PMID: 40458356. PMCID: PMC12129487. https://doi.org/10.7759/cureus.83422

19. Sabia R, Wagner M, Susa K, Lemke J, Rothermund L, Henne-Bruns D, Hillenbrand A. Calcitonin concentrations in patients with chronic kidney disease on hemodialysis in reference to parathyroidectomy. BMC Res Notes. 2019;12(1):439.

PMID: 31324271. PMCID: PMC6642600. https://doi.org/10.1186/s13104-019-4479-6

20. Mura C, Rodia R, Corrias S, Cappai A, Lai ML, Canu GL et al. Diffuse C-cells hyperplasia is the source of false positive calcitonin measurement in FNA washout fluids of thyroid nodules: A rational clinical approach to avoiding unnecessary surgery. Cancers (Basel). 2024;16(1):210.

PMID: 38201637. PMCID: PMC10777925. https://doi.org/10.3390/cancers16010210

21. Cremaschi A, Del Sindaco G, Pagnano A, Dolci A, Berkenou J, Rothenbuhler A et al. High prevalence of hypercalcitoninemia in a large cohort of adult and pediatric patients with PTH resistance syndromes. J Clin Endocrinol Metab. 2025;110(5):1334–41.

PMID: 38940443. PMCID: PMC12012675. https://doi.org/10.1210/clinem/dgae416

22. Trimboli P, Peloni G, Confalonieri D, Gamarra E, Piticchio T, Frasca F et al. Determinants of circulating calcitonin value: Analysis of thyroid features, demographic data, anthropometric characteristics, comorbidities, medications, and smoking habits in a population with histological full exclusion of medullary thyroid carcinoma. Front Oncol. 2024;14:1278816.

PMID: 38347847. PMCID: PMC10859508. https://doi.org/10.3389/fonc.2024.1278816

23. Maino F, Dalmiglio C, Benenati N, Campanile M, Pilli T, Forleo R et al. Calcitonin levels in thyroid disease are not affected by autoimmune thyroiditis or differentiated thyroid carcinoma. Eur Thyroid J. 2021;10(4):295–305.

PMID: 34395301. PMCID: PMC8314776. https://doi.org/10.1159/000511080

24. Giovanella L, D’Aurizio F, Petranovic Ovcaricek P. Circulating biomarkers in medullary thyroid carcinoma: Bridging laboratory complexities and clinical application through algorithm design. J Clin Med. 2025;14(16):5645.

PMID: 40869471. PMCID: PMC12386243. https://doi.org/10.3390/jcm14165645

25. Mater A, Boelen A, Heijboer AC, Hillebrand JJ. Thyroglobulin and calcitonin measurements: Pitfalls and future perspectives. J Endocrinol. 2024;264(1):e240156.

PMID: 39437178. https://doi.org/10.1530/JOE-24-0156

26. Censi S, Cavedon E, Fernando SW, Barollo S, Bertazza L, Zambonin L et al. Calcitonin measurement and immunoassay interference: A case report and literature review. Clin Chem Lab Med. 2016;54(12):1861–70.

PMID: 27166721. https://doi.org/10.1515/cclm-2015-1161

27. Zhang X, Liu Y, Liu X, Shu H, Dong Z. Experimental study of interference in calcitonin testing: A case report and literature review. Endocr Metab Immune Disord Drug Targets. 2024. Online ahead of print.

PMID: 38798210. https://doi.org/10.2174/0118715303287794240519191720

28. Camacho CP, Lindsey SC, Kasamatsu TS, Machado AL, Martins JR, Biscolla RP et al. Development and application of a novel sensitive immunometric assay for calcitonin in a large cohort of patients with medullary and differentiated thyroid cancer, thyroid nodules, and autoimmune thyroid diseases. Eur Thyroid J. 2014;3(2):117–24.

PMID: 25114875. PMCID: PMC4109516. https://doi.org/10.1159/000363055

29. Blind E, Raue F, Klaiber T, Zink A, Schroth J, Buhr H, Ziegler R. Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma. J Endocrinol Invest. 1992;15(2):93–98.

PMID: 1569295. https://doi.org/10.1007/BF03348671

30. Clausi C, Censi S, Zanin E, Messina G, Piva I, Basso D et al. Combining procalcitonin and calcitonin for the diagnosis of medullary thyroid cancer: A two-step approach. Clin Endocrinol (Oxf). 2025;103(4):587–95.

PMID: 40464083. PMCID: PMC12413671. https://doi.org/10.1111/cen.15287

31. Jandric M, Zlojutro B, Momcicevic D, Dragic S, Topolovac S, Kovacevic T, Kovacevic P. Incidental diagnosis of medullary thyroid microcarcinoma in COVID-19 patient with elevated procalcitonin levels. Arch Clin Cases. 2024;11(4):98–101.

PMID: 39639916. PMCID: PMC11615157. https://doi.org/10.22551/2024.45.1104.10297

32. Alves TG, Kasamatsu TS, Yang JH, Meneghetti MC, Mendes A, Kunii IS et al. Macrocalcitonin is a novel pitfall in the routine of serum calcitonin immunoassay. J Clin Endocrinol Metab. 2016;101(2):653–58.

PMID: 26647152. https://doi.org/10.1210/JC.2015-3137

33. Censi S, Manso J, Mian C. Other markers of medullary thyroid cancer, not only calcitonin. Eur J Endocrinol. 2023;188(1):lvac009.

PMID: 36651167. https://doi.org/10.1093/ejendo/lvac009